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Summary
Background and objectives Phosphate control impacts dialysis outcomes. Our aim was to define peritoneal
phosphate transport in peritoneal dialysis (PD) and to explore its association with hyperphosphatemia,
phosphate clearance (PPhCl), and PD modality.
Design, setting, participants, & measurements Two hundred sixty-four patients (61% on continuous ambula-
tory PD [CAPD]) were evaluated at month 12. PPhCl was calculated from 24-hour peritoneal effluent. Phos-
phate (Ph) and creatinine (Cr) dialysate/plasma (D/P) were calculated at a 4-hour 3.86% peritoneal equili-
bration test.
Results D/PPh correlated with D/PCr. PPhCl correlated better with D/PPh than with D/PCr. Prevalence of
hyperphosphatemia (5.5 mg/dl) was 30%. In a multiple regression analysis, only residual renal function
was independently, negatively associated with hyperphosphatemia; in anuric patients, only D/PPh was an
independent factor predicting hyperphosphatemia. D/PPh was 0.57  0.10, and according to this, 16% of
the patients were fast, 31% were fast-average, 35% were slow-average, and 17% were slow transporters.
PPhCl was 37.5  11.7 L/wk; it was lower in the slow transporter group (31  14 L/wk). Among fast and
fast-average transporters, PPhCl was comparable in both PD modalities. In comparison to automated PD,
CAPD was associated with increased PPhCl among slow-average (36  8 versus 32  7 L/wk) and slow
transporters (34  15 versus 24  9 L/wk).
Conclusions In hyperphosphatemic, particularly anuric, patients, optimal PD modality should consider peri-
toneal phosphate transport characteristics. Increasing dwell times and transfer to CAPD are effective strate-
gies to improve phosphate handling in patients with inadequate phosphate control on automated PD.
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Introduction
Hyperphosphatemia is common among dialysis pa-
tients and is a major risk factor for cardiovascular
mortality in both hemodialysis and peritoneal dialysis
(PD) patients (1–7). In PD patients, phosphate control
is known to deteriorate as residual renal function
(RRF) declines (8,9). In fact, although the importance
of RRF in maintaining serum phosphorus levels in PD
patients has already been established (8), the role of
peritoneal phosphate clearance in achieving adequate
phosphate homeostasis has not been well studied.
Dialytic phosphate clearance is the product of non-
modifiable peritoneal transport characteristics and
the modifiable components of dialysis prescription.
Whether creatinine may be used as a surrogate
marker of phosphate transport is now under debate.
Some authors consider that creatinine clearance mea-
surements provide a good estimate of phosphorus
clearance (10), whereas others showed that the peri-
toneal transport state defined by the creatinine equil-
ibration pattern is poorly predictive of daily phos-
phate clearance (11). In fact, until now, no studies
have tried to define peritoneal membrane phosphate
transport status in an prevalent adult PD population.
Finally, few studies have addressed the importance of
PD modality concerning dialytic phosphate clearance
(10,12).
Because of this, the objectives of our study were to
define peritoneal membrane phosphate transport sta-
tus in a large, prevalent adult PD population and to
explore its association with hyperphosphatemia,
phosphate peritoneal clearance, and PD modality.
Materials and Methods
This was a cross-sectional and retrospective study
conducted at the La Paz University Hospital Home
Dialysis Unit. From the 348 prevalent patients on PD
that were treated in our unit from January 1992 until
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January 2009, 264 patients were included in this cross-
sectional observational study. We excluded 84 patients
with 1 year of PD treatment. Each patient included was
evaluated at 12 months (1 year) after starting PD. Our
patients were receiving standard prescriptions of continu-
ous ambulatory peritoneal dialysis (CAPD) or automated
peritoneal dialysis (APD), according to European best
practice recommendations (13). Solutions with high cal-
cium content (3.5 mEq/L) were standardly prescribed in
the unit, unless the patient had sustained hypercalcemia.
Phosphate binders were prescribed, as appropriate, to
maintain serum phosphorus concentration between 3.5
and 5.5 mg/dl, according to the 2003 Kidney Disease Out-
comes Quality Initiative guidelines for mineral metabolism
(14). Residual renal function was calculated as the average
of 24-hour urinary urea and creatinine clearances. Stan-
dard parameters of dialysis adequacy were determined by
measuring total (renal and peritoneal) weekly urea clear-
ance (Kt/V) and creatinine clearance using standard meth-
ods (15). Dialysate creatinine concentration was corrected
for interference by glucose according to a reference for-
mula determined by our laboratory. Protein equivalent
nitrogen appearance (nPNA) was calculated using meth-
ods described by Randerson et al. (16) and normalized to
actual weight. Phosphate renal and peritoneal clearances
were calculated as follows: peritoneal phosphate clearance
(L/wk per 1.73 m2)  (dialysate phosphate in mg/dl/
plasma phosphate in mg/dl)  24-hour effluent dialysate
volume (L)  7 (corrected for 1.73 m2 BSA); renal phos-
phate clearance (L/wk per 1.73 m2)  (urine phosphate in
mg/dl/plasma phosphate in mg/dl)  24-hour urinary
volume (L)  7 (corrected for 1.73 m2 BSA). Additionally,
we performed a 3.86%, 4-hour glucose peritoneal equili-
bration test (PET). Dialysate/plasma (D/P) creatinine (Cr)
ratio and D/P phosphate (Ph) ratio were measured at 4
hours. The 24-hour dialysate collection was performed
exactly on the day before the realization of the PET for all
patients. Concerning phosphate transport status, our pa-
tients were classified as slow (D/P Ph  0.47), slow-aver-
age (0.47  D/P Ph 0.57), fast-average (0.57  D/P Ph
0.68), or fast (D/P Ph  0.68) transporters, according to
the mean  SD of the dialysate/plasma phosphate ratio
(D/P Ph). We also divided our patients by the dialysate/
plasma creatinine ratio (D/P Cr) as slow (D/P Cr  0.49),
slow-average (0.50  D/P Cr  0.64), fast-average (0.65 
D/P Cr  0.80), and fast (D/P Cr  0.81) transporters
according to the criteria defined by Twardowski et al. (17).
Results were expressed as frequencies and percentages
for categorical variables, mean  SD for continuous vari-
ables, and median and interquartile range for nonparamet-
ric data. Correlations between two continuous variables
were expressed as Pearson’s or Spearman’s correlations
coefficients. Differences between hyperphosphatemic (se-
rum phosphate  5.5 mg/dl) and normophosphatemic
(serum phosphate  5.5 mg/dl) patients were evaluated
using unpaired t test, Mann-Whitney U test, and 2 test as
appropriate. In the subanalysis of anuric patients, we an-
alyzed peritoneal phosphate clearance both as a continu-
ous and a categorical variable, according to the mean value
of peritoneal phosphate clearance (37.5 L/wk per 1.73 m2).
Multivariate analysis using conditional logistic regression
and multiple linear regression models (as appropriated)
were performed to analyze the determinants of hyperphos-
phatemia (serum phosphate being analyzed both as a con-
tinuous and categorical variable) at 1 year of treatment,
first in all of the patients and then focused on anuric
patients. The following variables were included in the
models: PD modality as a categorical variable (CAPD ver-
sus APD) and nPNA, peritoneal urea Kt/V, peritoneal
creatinine clearance, peritoneal phosphate clearance, D/P
Ph, D/P Cr, and RRF as continuous variables. We com-
pared clearances of small solutes (urea, creatinine, and
phosphate) according to PD modality (CAPD versus APD)
using the t test and Mann-Whitney U test, as appropriate.
Peritoneal phosphate transport was categorized according
to mean SD of D/P Ph. We compared clearances of small
solutes (urea, creatinine, and phosphate) across the four
categories of peritoneal membrane phosphate transport
status using one-way ANOVA and Kruskal-Wallis tests, as
appropriate. We finally explored the adequacy and phos-
phate clearances according to PD modality, controlling for
peritoneal phosphate transport status. P  0.05 was con-
sidered statistically significant. Statistical analysis was per-
formed using SPSS, version 15.0, for Windows software
(SPSS, Chicago, IL).
Results
Patient baseline characteristics are listed in Table 1. The
baseline evaluation (at 3 months) concerning peritoneal
membrane small solute transport and residual renal func-
tion (data not shown) was not significantly different from
that at 1 year. In the PET at 1 year, mean 4-hour D/P ratio
was 0.70  0.1 for creatinine and 0.57  0.1 for phosphate.
A close correlation was observed between D/P Ph and
D/P Cr at 1 year (r  0.81, P  0.0001; Figure 1, left).
Correlation between Creatinine Transport and Phosphate
Transport
Peritoneal phosphate clearance at 1 year correlatedbetterwith
peritoneal creatinine clearance at 1 year than with peritoneal
urea Kt/V at 1 year (r  0.650, P  0.0001 and r  0.451, P 
0.0001, respectively). Peritoneal phosphate clearance at 1 year
correlated better with D/P Ph at 1 year than with D/P Cr at
Table 1. Population baseline characteristics
Total (n  264)
Sex (male) 160 (60.6%)
Age (years) 51.4 16.0
CAPD/APD 160 (60.6%)/104 (39.4%)
Diabetes mellitus 46 (17.4%)
Renal diagnosis
Chronic glomerulonephritis 47 (17.8%)
Tubulointersticial
nephropathy
47 (17.8%)
Diabetic nephropathy 37 (14.0%)
Poliquistic autossomic
dominant nephropathy
29 (11.0%)
Hypertensive
nephrosclerosis
29 (11.0%)
Unknown 38 (14.4%)
Others 37 (14.0%)
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1 year (r  0.490, P  0.0001 and r  0.400 P  0.0001,
respectively).
Hyperphosphatemia, RRF, and Phosphate Clearance
At 1 year of treatment, 79 patients (30%) had hyperphos-
phatemia (serum phosphate levels5.5 mg/dl). Phosphate lev-
els correlated negatively with residual renal function and renal
phosphate clearance (r  0.290, P  0.0001 and r  0.225,
P 0.008, respectively) but did not correlatewith nPNAorwith
peritoneal small solute clearances. In a multiple regression anal-
ysis, only RRF was independently and negatively associated
with hyperphosphatemia [Exp(B) 0.75; 95% confidence inter-
val, 0.64 to 0.89; P  0.001]. The same results were obtained
considering serumphosphate as a continuous variable (data not
shown). In fact, serum phosphate levels were 5.5mg/dl
in 43.6% of anuric patients (n  78) versus 24.2% of
patients with RRF (n  186, P  0.002). Among patients
with RRF, those with hyperphosphatemia had signifi-
cantly lower renal phosphate clearances than patients
with serum phosphate 5.5mg/dl (28.2  21.1 versus
45.5  30.1 L/wk per 1.73 m2, P  0.018), whereas
peritoneal phosphate clearance was similar in the two
groups (34.7  10.7 versus 34.6  10.9 L/wk per 1.73 m2;
Table 2).
Anuric Patients
Anuric hyperphosphatemic patients had lower mean
levels of phosphate peritoneal clearance and a statistically
significant slower membrane phosphate transport rate
(Table 2). Concerning adequacy parameters among an-
uric patients, we observed that 97.2% had a peritoneal
Kt/V of 1.7 or greater and 83.3% had a peritoneal cre-
atinine clearance of 45 L/wk per 1.73 m2 or greater.
However, only 68.8% had a peritoneal phosphate clear-
ance of 37.5 L/wk per 1.73 m2 or greater (equal or
greater than the mean peritoneal phosphate clearance of
the population in this analysis). In fact, serum phosphate
levels were 5.5mg/dl in 62.5% of anuric patients with
peritoneal phosphate clearance 37.5 L/wk per 1.73 m2
(n  24) versus 33.9% of anuric patients with a peritoneal
phosphate clearance of 37.5 L/wk per 1.73 m2 (n  54,
P  0.019). In a multiple regression analysis, only D/P
Ph was independently and negatively associated with
hyperphosphatemia in anuric patients [Exp(B)  0.003,
95% confidence interval, 0.001 to 0.50; P  0.026]. We
obtained the same results considering serum phosphate
as a continuous variable (data not shown).
Modality of PD Controlling for Peritoneal Membrane
Phosphate Transport
To compare phosphate clearances according to PD mo-
dality, also controlling for peritoneal membrane phosphate
transport rate, we studied 260 patients (we excluded 4
patients without 1-year PET evaluation): 157 (60.4%) were
treated with CAPD and 103 (39.6%) with APD. We de-
tected a different categorization of patients concerning
phosphate and creatinine peritoneal transports. Relative to
peritoneal phosphate transport, 42 (16.2%) patients were
classified as fast transporters (D/P Ph  0.68), 81 (31.2%)
as fast-average transporters (0.57  D/P Ph 0.68), 92
(35.4%) as slow-average transporters (0.47  D/P Ph 
0.57), and 45 (17.3%) as slow transporters (D/P Ph  0.47).
Concerning peritoneal creatinine transport, 30 patients
(11.5%) were classified as fast transporters (D/P Cr 0.81),
163 (62.7%) as fast-average transporters (0.65  D/P Cr 
0.80), 67 (25.8%) as slow-average transporters (0.50  D/P
Cr  0.64), and 0 as slow transporters (D/P Cr  0.49;
Table 3; Figure 1, right).
According to PD modality, patients treated with APD
had higher peritoneal urea Kt/V than patients treated with
CAPD (1.71  0.5 versus 1.45  0.3, P  0.0001), but there
was no difference in peritoneal creatinine clearance or in
peritoneal phosphate clearance between those treated with
APD or CAPD (Table 3). Patients with fast-transport mem-
branes had a higher peritoneal urea Kt/V, a higher peri-
toneal creatinine clearance, and a higher peritoneal phos-
phate clearance than the rest of categories (Table 4).
When peritoneal phosphate clearance by modality was
examined for each phosphate membrane category, there
was no significant difference in phosphate clearance be-
Figure 1. | (Left) Relation between D_P Ph_1y (dialysate to plasma phosphate ratio) and D_PCr_1y (dialysate to plasma creatinine ratio).
(Right) Categorization of patients concerning phosphate peritoneal transport (according to mean  SD of D/P Ph) and creatinine peritoneal
transport (according to Twardowski et al.).
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Table 2. Dialysis adequacy, phosphate clearance, and peritoneal transport status in patients with a serum phosphorous level of <5.5
mg/dl versus >5.5 mg/dl and stratified according to residual renal function at 1 year of treatment
Serum Phosphate
All
Patients
n  264
Patients with RRF Anuric Patients
5.5 mg/
dl
(n  141)
5.5 mg/
dl
(n  45)
5.5 mg/
dl
(n  44)
5.5 mg/
dl
(n  34)
Total weekly urea Kt/V 2.7 0.7a 2.1  0.4a 2.1  0.3 2.0 0.3 2.4 0.7
Peritoneal weekly urea Kt/V 1.5 0.4 1.4 0.3 2.1  0.3 2.0 0.3 1.6 0.4
Renal weekly urea Kt/V 1.2 0.8a 0.7  0.5a 0.8 0.8
Total weekly CCr (L/wk per
1.73 m2)
93.7 34.5a 68.0 20.4a 52.6 10.3 53.7 7.8 79.0  32.7
Peritoneal weekly CCr (L/wk
per 1.73 m2)
35.5 9.8 34.2 7.3 52.6 10.3 53.7 10.1 39.4 11.8
Renal weekly CCr (L/wk
per 1.73 m2)
58.2 37.1a 33.8 22.2a 39.6 38.2
Total weekly CPh (L/wk
per 1.73 m2)
80.1 29.9a 62.9 21.5a 46.6 10.6 43.4 11.3 61.6  27.2
Peritoneal weekly CPh (L/wk
per 1.73 m2)
34.6 10.9 34.7 10.7 46.6 10.6 43.4 11.3 37.5 11.7
Renal weekly CPh (L/wk per
1.73 m2)
45.5 30.1a 28.2 21.1a 22.2 29.6
RRF (ml/min per 1.73 m2) 5.8  3.7a 3.7  2.5a 3.8 3.8
D/P Cr 0.69 0.1 0.70 0.1 0.73 0.1 0.71 0.1 0.70 0.09
D/P Ph 0.56 0.1 0.58 0.1 0.63 0.1b 0.57 0.1b 0.57 0.11
nPNA (g/kg per day) 1.2 0.3 1.2 0.3 1.1  0.3 1.1 0.2 1.2 0.3
Values are expressed as mean  SD. CCr, creatinine clearance; CPh phosphate clearance.
aP  0.05 patients with RRF and serum phosphorous 5.5 mg/dl versus patients with RRF and serum phosphorous 5.5 mg/dl,
according to independent sample t test.
bP  0.05 anuric patients with serum phosphorous 5.5 mg/dl versus anuric patients with phosphorous 5.5 mg/dl, according to
independent sample t test.
Table 3. Peritoneal membrane transport status and solute clearances according to PD modality, at 1 year of treatment
Variable CAPD APD P
Peritoneal urea Kt/V 1.45 0.3 1.71 0.5 0.0001a
Peritoneal creatinine clearance (L/wk per 1.73 m2) 38.7 9.1 40.0 13.5 0.527
Peritoneal phosphate clearance (L/wk per 1.73 m2) 36.5 9.2 36.7 12.1 0.928
D/P Cr 0.69 0.1 0.71 0.1 0.319
fast transporter 17/30 (56.7%) 13/30 (43.3%)
fast-average transporter 98/163 (60.1%) 65/163 (39.9%)
slow-average transporter 42/67 (62.7%) 25/67 (37.3%)
slow transporter 0 0
D/P Ph 0.61 0.1 0.61 0.1 0.884
fast transporter 23/42 (54.8%) 13/42 (45.2%)
fast-average transporter 49/81 (60.5%) 32/81 (39.5%)
slow-average transporter 52/92 (56.5%) 40/92 (43.5%)
slow transporter 33/45 (73.3%) 12/45 (27.7%)
Values are expressed as frequencies and percentages for categorical variables, mean  SD for continuous variables. Patients are
categorized, concerning creatinine transport status, as slow (D/P Cr  0.49), slow-average (0.50  D/P Cr  0.64), fast-average
(0.65  D/P Cr  0.80), and fast (D/P Cr  0.81) transporters, according to the criteria defined by Twardowski et al..
Patients are categorized, concerning phosphate transport status, as slow (D/P Ph  0.47), slow-average (0.47  D/P Ph 
0.57), fast-average (0.57  D/P Ph  0.68), or fast (D/P Ph  0.68) transporters, according to mean  SD of dialysate/
plasma phosphate ratio (D/P Ph).
aP  0.005 comparisons between patients in CAPD versus APD using the t test if data were parametric and the Mann-Whitney U
test if nonparametric.
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tween the modalities in the fast and fast-average transport
categories (Table 5). However, in the slow-average and
slow categories, treatment with CAPD was associated with
significantly higher phosphate clearance than with APD
(Table 5). We did not found any significant difference in
RRF or in renal phosphate clearance between the four
groups (slow, slow-average, fast-average, and fast trans-
porters) that could indirectly interfere on peritoneal phos-
phate transport. There was no significant difference in
peritoneal creatinine clearance between the two PD modal-
ities across any of the membrane transport categories (Ta-
ble 5).
Discussion
Our study highlighted that, other than RRF, peritoneal
phosphate transport rate and clearance evaluations are
additional parameters that can be used to optimize phos-
phorus control in PD patients.
Hyperphosphatemia is highly prevalent in PD patients
and is a strong predictor of overall and cardiovascular
mortality (1–4). Although elimination of inorganic phos-
phate by dialysis is a cornerstone in the management of
hyperphosphatemia, the subject of phosphate handling by
PD is scarcely addressed and has not been completely
studied. Phosphate transport across the peritoneum is in-
fluenced by osmotic, chemical, and electrical gradients, as
well as by transmembranous active phosphate transporters
and thus is more complex than peritoneal urea or creati-
nine transport (18–20). As in Sedlacek et al. (10), our study
showed that peritoneal phosphate clearance is more
closely related with peritoneal creatinine clearance than
with peritoneal urea clearance. This finding must be re-
lated to some special features of the phosphate molecule,
because the molecular weight of phosphate (96 Da) lies
right between those of urea (60 Da) and creatinine (130 Da),
and the molecular radius of phosphate (2.8 Å) is closer to
that of creatinine (3.0 Å) than urea (1.8 Å). However,
concerning peritoneal membrane transport status, we
showed a closer relation with peritoneal phosphate clear-
ance and D/P Ph than with D/P Cr in a 4-hour, 3.86%
glucose PET. This finding is even more important once
residual renal function is lost. In that circumstance, the
peritoneal membrane phosphate transport status plays the
most important role in the management of hyperphos-
Table 4. Solute clearances comparison across peritoneal membrane phosphate transport status, at 1 year of treatment
Variable Fast Fast-Average Slow-Average Slow P
Peritoneal urea Kt/V 1.87 0.5 1.63 0.5 1.58 0.4 1.51 0.4 0.016a
Peritoneal creatinine clearance
(L/wk per 1.73 m2)
49.3 12.2 41.8 13.9 37.1 8.8 34.3 12.2 0.005a
Peritoneal phosphate clearance
(L/wk per 1.73 m2)
47.4 12.6 39.4 9.9 34.0 7.6 31.4 14.3 0.0001a
Values expressed as mean  SD. Patients classified as slow, slow-average, fast-average. or fast transporters, according to mean 
SD of dialysate plasma phosphate ratio (D/P Ph) at a 4-hour, 3.86% glucose PET.
aP  0.005 intergroup solute clearances comparison across the four transport groups using one-way ANOVA if data were
parametric and Kruskal-Wallis test if nonparametric.
Table 5. Peritoneal urea, creatinine, and phosphate clearances according to peritoneal membrane phosphate transport status and PD
modality, at 1 year of treatment
CAPD APD P
Peritoneal Kt/V
fast 1.47 0.3 1.99 0.4 0.026a
fast-average 1.74 0.51 1.56 0.5 0.054
slow-average 1.66 0.2 1.46 0.4 0.242
slow 1.58 0.3 1.44 0.3 0.720
Peritoneal creatinine clearance
fast 49.6 8.8 54.4 12.8 0.249
fast-average 41.0 14.2 42.3 14.0 0.775
slow-average 41.1 6.2 37.1 11.5 0.968
slow 37.2 5.1 31.8 13.2 0.279
Peritoneal phosphate clearance
fast 46.9 12.6 48.1 13.0 0.755
fast-average 39.3 10.4 39.6 9.3 0.865
slow-average 35.9 7.8 31.6 6.6 0.006a
slow 33.9 15.2 24.5 9.0 0.049a
Values expressed as mean  SD. Patients classified as slow, slow-average, fast-average, or fast transporters, according to mean 
SD of dialysate plasma phosphate ratio (D/P Ph) at a 4-hour, 3.86% glucose PET.
aP  0.005 intergroup comparisons between patients in CAPD versus APD using the t test if data were parametric and the Mann-
Whitney U test if nonparametric.
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phatemia by PD. Hence, when we divided patients accord-
ing to the classical Twardowski categories of peritoneal
membrane transport status, we found that only 67 patients
(25.8%) had a slow-average transport status, and none fell
into the slow transport status category. However, when
divided according to mean  SD of D/P Ph, 137 patients
(52.7%) had a slow-average/slow transport status, and
these patients had significantly lower values of peritoneal
small solute clearances than the patients in the fast/fast-
average transport category. This means that D/P Cr is not
a sufficiently accurate measure to classify patients for peri-
toneal membrane phosphate transport status. The aqueous
layer that surrounds the phosphate molecule, increasing its
effective molecular weight, may be one of the reasons why
creatinine apparently reaches a more rapid equilibration
across the peritoneal membrane than phosphate (18,20,21).
Previous studies that made direct comparisons of phos-
phate clearance between CAPD and APD have not shown
significant differences in peritoneal phosphate clearance
(10,22) or worse peritoneal phosphate clearance on CAPD
(23). These studies were limited by small sample size and
no adjustment for peritoneal membrane transport cate-
gory. Sedlaceak et al. (10) and Badve et al. (12) reported that
phosphate clearance is increased in fast transporters com-
pared with slow transporters in CAPD and APD when
peritoneal transport status is defined according to Twar-
dowski categories of D/P Cr in a 4-hour, 3.86% glucose
PET. Our study expands on the work of these groups
because we compared phosphate clearance between CAPD
and APD by adjusting for peritoneal membrane phosphate
transport category. In fact, when we compared modalities
across each peritoneal phosphate transport category, we
found that PD modality is a significant determinant of
phosphate handling, in subgroups of patients, with supe-
rior peritoneal phosphate clearance associated with CAPD
treatment among slow and slow-average transporters.
Thus, our data suggest that peritoneal membrane phos-
phate transport status should also be considered when
optimizing the PD prescription, especially among anuric
patients. Like Wang et al. (8), we showed that anuric PD
patients have poorer phosphate control than those with
residual renal function, and in these patients, serum phos-
phate is an inverse function of the peritoneal phosphate
clearance. Our findings that treatment with CAPD was
associated with an increase in phosphate clearance of
13.6% among slow-average transporters and 38.4% among
slow transporters, compared with APD, suggest that PD
prescription may play an important role in phosphate han-
dling, especially among anuric patients with slow trans-
port categories.
The International Society for Peritoneal Dialysis guide-
lines on PD adequacy recommend a urea Kt/V target of
1.7 and a separate target of 45 L/wk per 1.73 m2 of
creatinine clearance (13). Our data suggest that focusing
only on urea and creatinine for assessment of dialysis
adequacy may result in inadequate clearance of phosphate.
In fact, although the majority of our anuric patients accom-
plished those adequacy targets, 43.6% of them had hyper-
phosphatemia. From these, 44% had a peritoneal phos-
phate clearance 37.5 L/wk per 1.73 m2, which might be
amenable by adjusting PD prescription to peritoneal mem-
brane phosphate transport rate, because 80% of them were
slow/slow-average phosphate transporters, and 50% of
these patients were on APD.
To our knowledge, this is the first study that defines
peritoneal membrane phosphate transport status in a large,
prevalent adult PD population and explores its association
with hyperphosphatemia and peritoneal phosphate clear-
ance.
One limitation is that this is a cross-sectional and obser-
vational study. Although we assessed a cross-section of the
PD population who were receiving adequate dialysis on
CAPD or APD, we did not attempt to assess the effect of
tidal regimens, dwell times, or number of cycles on phos-
phate clearance. Another limitation of our study is that the
phosphate binding prescription was not included. How-
ever, the lack of correlation between indirect protein intake
(nPNA) with serum phosphate that we found, the univer-
sal uncertainty about phosphate binder accomplishment,
and the fact that we focused our study on peritoneal phos-
phate elimination, may neutralize the effect of these limi-
tations.
Conclusions
This study contributes to our understanding of perito-
neal phosphate clearance by highlighting the importance
of establishing peritoneal membrane phosphate transport
status. In hyperphosphatemic and/or anuric patients, the
decision on the optimal PD modality should also take into
account peritoneal phosphate transport characteristics and
not just urea Kt/V or peritoneal creatinine clearance. In-
creasing dwell times or transfer to CAPD could be effective
strategies to improve phosphate handling in patients with
inadequate phosphate control on APD.
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